▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1182 by analyst upside · 2026-09-27
LMRI
Lumexa Imaging Holdings, Inc.
Healthcare · Market Cap $981M · P/E 0x
ANALYST PRICE TARGET
+72.6%
implied upside to consensus target
Current Price $10.21
Consensus Target $17.62
Bull Target $23.0
Bear Target $13.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
0
Sell
0
52-Week Low $6.45
52-Week High $19.45
YTD Return -41.8%
FUNDAMENTALS
Market Cap $981M
P/E Ratio (TTM) N/A
Forward P/E 11.4x
EPS (TTM) $-0.29
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.0B
Profit Margin -2.7%
52-WEEK RANGE
52-Week Low $6.45
52-Week High $19.45
Current Price $10.21
Bear Target $13.0
Bull Target $23.0
● Now $10.21 ● Target $17.62
TRADING DATA
Avg Volume 459K
YTD Return -41.8%
Analyst Count 8
Consensus Buy
Upside to Target +72.6%
Last Updated 2026-09-27

ANALYST SUMMARY

Lumexa Imaging Holdings, Inc. (LMRI) is currently trading at $10.21 with a Wall Street consensus price target of $17.62, implying potential upside of 72.6% over the next 12 months. 8 analysts currently cover LMRI, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $23.0, while the most cautious has a target of $13.0.

LMRI operates in the Healthcare sector with a market capitalisation of $981M. The stock is down 41.8% year-to-date and is currently trading near the lower end of its 52-week range of $6.45 – $19.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LMRI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Keybanc ● Initiated
Overweight 2026-09-25 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-28 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-20 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-04-14 Building track record
Raymond James ↑ Upgrade
Outperform → Strong Buy 2026-02-09 Building track record
Raymond James ● Initiated
Outperform 2026-01-05 Building track record
Barclays ● Initiated
Overweight 2026-01-05 Building track record
Wells Fargo ● Initiated
Overweight 2026-01-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
17/30
Consensus clarity
10/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →